Acrivon Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Acrivon Therapeutics, Inc. (ACRV) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $4.07 per share for the 3-month period ending 2022-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-11-09
- Acrivon Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-09-30 was $4.07.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month |
|---|---|
| 2022-09-30 | $4.07 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |